Related Experiment Video
Updated: Mar 23, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
11.0K
Azithromycin induced bullous fixed drug eruption
Anupam Das1, Karan Sancheti1, Indrashis Podder1
1Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India.
Indian Journal of Pharmacology
|March 22, 2016
Summary
Fixed drug eruption (FDE) is a common skin reaction. This report details the first known case of azithromycin causing bullous FDE, a severe form with blisters.
Area of Science:
- Dermatology
- Clinical Medicine
- Pharmacovigilance
Background:
- Fixed drug eruption (FDE) is a prevalent dermatological condition.
- FDE presents as erythematous patches, potentially developing into blisters (bullous FDE).
- Various medications can trigger FDE, necessitating ongoing identification of causative agents.
Observation:
- A patient presented with clinical manifestations consistent with FDE.
- The patient had recently been administered azithromycin.
- The eruption progressed to a bullous form.
Findings:
- The case describes azithromycin as the causative agent for bullous fixed drug eruption.
- This represents the first documented instance of azithromycin-induced bullous FDE.
- Diagnostic evaluation confirmed the link between azithromycin use and the observed dermatological reaction.
Implications:
- Highlights the potential of azithromycin to induce severe cutaneous adverse reactions.
- Emphasizes the importance of considering azithromycin in the differential diagnosis of bullous drug eruptions.
- Contributes to the pharmacovigilance data on azithromycin and underscores the need for clinician awareness.
More Related Videos
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
129
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
129
01:27Allergic Drug Reactions
1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
01:01Hypersensitivity Reactions: Cytolytic Reactions
115
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
115
01:19Hypersensitivity Reactions: Immune-Complex Reactions
127
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
127
01:29Drugs for Treatment of Ulcerative Colitis in IBD
605
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K